Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vopratelimab
- Development stage
- Phase 2
- Lead developer
- Concentra Biosciences
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vopratelimab is an agonistic humanized monoclonal antibody that targets the inducible T-cell co-stimulator (ICOS; CD278) receptor on certain T cells. By binding to ICOS, vopratelimab modulates immune responses, enhancing the activity of follicular helper T cells and promoting B cell maturation and immunoglobulin production. This mechanism provides potential antineoplastic effects and may restore humoral immunity in conditions such as common variable immunodeficiency (CVID). Vopratelimab has been investigated both as a monotherapy and in combination with immune checkpoint inhibitors like nivolumab for advanced or refractory solid tumors, including non–small cell lung cancer. The drug was initially developed by Jounce Therapeutics and is now being developed by Concentra Biosciences.
- Other names
- vopratelimab
02
Targets
ICOS (Inducible T-cell costimulator)
Beyond the preview
Go deeper on vopratelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vopratelimab.